Landre T, et al. - A meta-analysis of published randomized studies found on PubMed with the keywords “metastatic colorectal cancer,” “elderly,” “oxaliplatin,” “irinotecan,” “bevacizumab,” and “survival,” was performed to determine the impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer (MCRC) in elderly patients. According to the findings obtained, the addition of bevacizumab to fluoropyrimidin seems more effective in terms of overall survival or progression-free survival vs the addition of oxaliplatin or irinotecan in previously untreated elderly patients with MCRC.